MONDAY, OCTOBER 23, 2017

Agenus Inc. finalizes transaction terms with Oberland Capital

Agenus Inc., an immunology company that discovers and creates novel treatments for diseases like cancer, recently announced that it has finalized its non-dilutive royalty transactions pursuant to a note purchase agreement with Oberland Capital Management LLC, the leader of the investor group. Read More »

Mobile phone records may predict dengue fever epidemics

Harvard T.H. Chan School of Public Health said Monday that its researchers found that mobile phone records may be useful in predicting and timing the geographical spread of dengue fever epidemics. Read More »

VBI Vaccines receives grant to advance RSV candidate

VBI Vaccines Inc. recently received approximately $265,000 in grants to further develop the company’s eVLP Platform, which will be used to create a respiratory syncytial virus (RSV) vaccine candidate. Read More »

Doctors overestimate their Ebola assessment abilities

A recent survey of primary care physicians show that many of them overestimate their own abilities to assess potential Ebola cases and explain the risks of Ebola to their patients. Read More »

Small antibodies suggest vulnerability in parasites that cause diseases

Scientists from Whitehead Institute have found a potential target for drugs that could stop parasites from entering host cells thanks to an enzyme that is important to the parasite’s infectious behavior, especially for malaria and toxoplasmosis. Read More »

Cell phone data to monitor spread of infectious diseases

Vast datasets from tracking mobile phone data could allow health professionals to track the infectious diseases that spread each season. Read More »

Visterra medication proves effective against influenza strains

Visterra Inc., a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains. Read More »

New England Journal of Medicine reports on PMO-based therapeutic

On Wednesday, the New England Journal of Medicine published clinical data for AVI-7288, a PMO-plus antisense oligonucleotide, demonstrating the drug's safety. Read More »

New Visterra antibody broadly neutralizes dengue virus in studies

Visterra Inc., a clinical-stage biotechnology company, recently announced that its novel antibody known as VIS513 has shown positive results in its preclinical studies, where the antibody broadly neutralized all four dengue virus serotypes. Read More »

New study shows U.S. hospitalizations for adults with pneumonia

The Centers for Disease Control and Prevention (CDC) recently published a study detailing the cause of pneumonia hospitalizations for adults in the U.S. Read More »

Robin David Isaacs new chief medical officer at Entasis Therapeutics

Entasis Therapeutics, a company that uses its expertise and unique pathogen-targeted approach for creating and advancing new antibacterials, recently announced that it has made Robin David Isaacs, M.D., its new chief medical officer. Read More »

Vaccine products in R&D triples over last 10 years

The Tufts Center for the Study of Drug Development recently conducted a study, which showed that in the past 10 years vaccine products within the research and development pipeline have more than tripled. Read More »

Harvard team identifies protien required for viral replication

Harvard Medical School (HMS) said Thursday that researchers recently identified the vesicular stomatitis virus (VSV) protein structure that the virus needs in order to multiply and take over the body. Read More »

Studies explore drug-resistant antibiotics

Researchers are conducting studies to further understand and develop antibiotics to fight against drug-resistant illnesses. Read More »

TB can hide in bone marrow stem cells

A recent study conducted by the Forsyth Institute has shown that latent Tuberculosis (TB) bacteria uses the low oxygen (hypoxia) niches in bone marrow stem cells to hide from the immune system. Read More »

Second measles case of 2015 confirmed in Massachusetts

The Massachusetts Department of Public Health (MDPH) recently confirmed the second measles case in Massachusetts for 2015. Read More »

Synthetic vaccine particles may be crucial to mucosal vaccine research

Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues. Read More »

C. Evan Ballantyne takes over as chief financial officer at Agenus

Agenus, Inc., an immunology company that creates novel treatments for cancers and similar diseases, said Wednesday that C. Evan Ballantyne will be its new chief financial officer.Ballantyne has over 30 years of experience with financial and operational work. Read More »

Researchers begin Phase II trial for diabetes reversing vaccine

Researchers from the Massachusetts General Hospital recently received approval from the U.S. Food and Drug Administration (FDA) to begin a Phase II clinical trial to test a generic vaccine’s ability to reverse advanced Type 1 diabetes. Read More »

MIT investigates better methods for preventing and responding to flu outbreaks

Researchers from MIT recently published a paper that evaluates the best methods of reducing the likelihood of contracting the flu by regularly using non-pharmaceutical interventions (NPIs) and effectively deploying the vaccine. Read More »